| Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210) |
|---|
| 10/28/2004 | WO2004092411A1 Insulin-induced gene as therapeutic target in diabetes |
| 10/28/2004 | WO2004092398A2 Nucleic acid sequences encoding proteins associated with abiotic stress response and plant cells and plants with increased tolerance to environmental stress |
| 10/28/2004 | WO2004092397A2 Tmprss2 regulatory sequences and uses thereof |
| 10/28/2004 | WO2004092396A2 Flap endonuclease 1 (fen1) regulatory sequences and uses thereof |
| 10/28/2004 | WO2004092395A2 Modulators of telomere stability |
| 10/28/2004 | WO2004092391A2 Metabolic engineering for enhanced production of chitin and chitosan in microorganisms |
| 10/28/2004 | WO2004092390A2 Dna constructs and methods to enhance the production of commercially viable transgenic plants |
| 10/28/2004 | WO2004092389A2 New process for improving the manufacture of clavams e.g. clavulanic acid |
| 10/28/2004 | WO2004092387A1 Viral vectors expressing fusion of viral large envelope protein and protein of interest |
| 10/28/2004 | WO2004092386A2 Inducing a t cell response with recombinant pestivirus replicons or recombinant pestivirus replicon-transfected dendritic cells |
| 10/28/2004 | WO2004092385A1 METHOD OF DETECTING β3 ADRENALINE RECEPTOR MUTANT GENE AND NUCLEIC ACID PROBE AND KIT THEREFOR |
| 10/28/2004 | WO2004092384A2 Means and methods for diagnosing and treating affective disorders |
| 10/28/2004 | WO2004092383A2 RNA INTERFERENCE MEDIATED INHIBITION OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS) VIRUS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 10/28/2004 | WO2004092382A1 Method of detecting pancryatic islet amyloid protein mutant gene and nucleic acid probe and kit therefor |
| 10/28/2004 | WO2004092381A1 Ubiquitin fused gene promoter and utilization thereof |
| 10/28/2004 | WO2004092380A1 Ubiquitin fused gene promoter and utilization thereof |
| 10/28/2004 | WO2004092379A2 Method for treatment of angiogenic disorders |
| 10/28/2004 | WO2004092378A2 Method for treatment of cancerous angiogenic disorders |
| 10/28/2004 | WO2004092376A1 Method of designing normally orthogonalized sequences, method of producing nucleic acids being normally orthogonalized sequences and nucleic acids obtained thereby |
| 10/28/2004 | WO2004092375A2 Ligation-based synthesis of oligonucleotides with block structure |
| 10/28/2004 | WO2004092374A1 METHOD OF REGULATING ACTIVATION OF TRANSCRIPTIONAL FACTORS NF-AT, AP-1 AND NF-κB USING EFFECT OF ACTIVATING ADAPTOR PROTEIN 3BP2 |
| 10/28/2004 | WO2004092372A1 Gene capable of imparting salt stress resistance |
| 10/28/2004 | WO2004092371A1 Mouse with deficiency of glutamate trasnporter glast function |
| 10/28/2004 | WO2004092367A1 Use of genes for increasing the oil content in plants |
| 10/28/2004 | WO2004092366A1 Mtehod of distinguishing ear shape and resistance against gibberella zeae and method of improving barley plant using the same |
| 10/28/2004 | WO2004092364A1 Probable germin protein 4 gene promoter and utilization thereof |
| 10/28/2004 | WO2004092361A1 Process for isolating and purifing ovine hyaluronidase |
| 10/28/2004 | WO2004092356A2 Method for obtaining mastocyte lines from porcine tissue and method for production of heparin type molecules |
| 10/28/2004 | WO2004092351A2 Production of a transgenic avian by cytoplasmic injection |
| 10/28/2004 | WO2004092349A2 Plant cells and plants with increased tolerance to environmental stress |
| 10/28/2004 | WO2004092348A2 Method for production of oncolytic adenoviruses |
| 10/28/2004 | WO2004092345A2 Transformation of brassica |
| 10/28/2004 | WO2004092338A2 Compositions, splice variants and methods relating to cancer specific genes and proteins |
| 10/28/2004 | WO2004092326A2 Methods and compositions to increase plant resistance to stress |
| 10/28/2004 | WO2004092218A1 Process for producing recombinant antithrombin |
| 10/28/2004 | WO2004092216A1 Carcinoembryonic antigen (cea) lacking a signal peptide, nucleic acid encoding it and fusion of cea with a t cell epitope and their use for the treatment and/or prophylaxis of cancer |
| 10/28/2004 | WO2004092215A2 Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2 |
| 10/28/2004 | WO2004092214A2 Affinity purification system using troponin molecules as affinity ligands |
| 10/28/2004 | WO2004092199A2 Method for identifying modulators of g protein coupled receptor signaling |
| 10/28/2004 | WO2004092194A2 Chimeric polypeptides and their use |
| 10/28/2004 | WO2004091664A1 Cytoplasmic malate dehydrogenase inhibitor |
| 10/28/2004 | WO2004091572A2 Cochleate compositions directed against expression of proteins |
| 10/28/2004 | WO2004091525A2 Morpholino imaging and therapy via amplification targeting |
| 10/28/2004 | WO2004091515A2 iRNA CONJUGATES |
| 10/28/2004 | WO2004091479A2 Gene amplification and overexpression in cancer |
| 10/28/2004 | WO2004091388A1 LIVIN-SPECIFIC siRNAS FOR THE TREATMENT OF THERAPY-RESISTANT TUMORS |
| 10/28/2004 | WO2004091288A2 Correcting mitotic spindle defects in somatic cell nuclear transfer |
| 10/28/2004 | WO2004091287A2 Genes responsible for vernalization regulation in temperate grasses and uses thereof |
| 10/28/2004 | WO2004078982A3 Modified low molecular weight glutenin with reduced risk to patients with celiak disease |
| 10/28/2004 | WO2004076626A3 Methods of gene therapy for treating disorders of the ear by administering a vector encoding an atonal-associated factor |
| 10/28/2004 | WO2004076618A3 Genetically modified non-human mammals and cells |
| 10/28/2004 | WO2004076617A3 Method for the production of polyunsaturated fatty acids |
| 10/28/2004 | WO2004074439A3 An expression cassette and vector for transient or stable expression of exogenous molecules |
| 10/28/2004 | WO2004074311A3 Human cyclooxygenase-3 and uses thereof |
| 10/28/2004 | WO2004072279A3 Proteases |
| 10/28/2004 | WO2004072251A9 Directed genetic modifications of human stem cells |
| 10/28/2004 | WO2004071418A3 Compounds for the treatment of systemic lupus erythematosus |
| 10/28/2004 | WO2004070022A3 Use of oxalate deficient aspergillus niger strains for producing a polypeptide |
| 10/28/2004 | WO2004069995A3 Transposon-based targeting system |
| 10/28/2004 | WO2004069994A3 Transposon-based targeting system |
| 10/28/2004 | WO2004058813A3 Peptides having a high cysteine content |
| 10/28/2004 | WO2004057000A3 Methods and compositions for modulating tuber formation in tuber-producing plants |
| 10/28/2004 | WO2004056857A3 Use of the multifunctional transcription factor yin-yang-1 and variants thereof for treating illnesses, especially type 1 diabetes |
| 10/28/2004 | WO2004055190A3 Immunization of fish with plant-expressed recombinant proteins |
| 10/28/2004 | WO2004053055A8 Transgenic maize with enhanced phenotype |
| 10/28/2004 | WO2004053054A3 Nk cell receptor conjugates for treating malignancies |
| 10/28/2004 | WO2004052929A3 Recombinant cell line |
| 10/28/2004 | WO2004050885A3 Control of apoptosis using a complex of an oligonucleotide and a regulatory peptide |
| 10/28/2004 | WO2004046362A3 Hydroxypyruvate reductase promoter elements and methods of use thereof in plants |
| 10/28/2004 | WO2004046339A3 Caged sensors, regulators and compounds and uses thereof |
| 10/28/2004 | WO2004043386A3 Molecules preferentially associated with effector t cells and methods of their use |
| 10/28/2004 | WO2004041857A3 Mutant of clostridium difficile toxin b and methods of use |
| 10/28/2004 | WO2004039825A3 Method for the synthesis of a bifunctional complex |
| 10/28/2004 | WO2004035748A3 Methods using gene trapped stem cells for marking pathways of stem cell differentiation and making and isolating differentiated cells |
| 10/28/2004 | WO2004029197A3 Co-stimulatory molecules |
| 10/28/2004 | WO2004024936A3 Mutant forms of glutamate receptors mglur2 and mglur3 |
| 10/28/2004 | WO2004022765A3 Method for hydrolysing carotenoids esters |
| 10/28/2004 | WO2004018709A3 Single nucleotide polymorphisms predicting adverse drug reactions and drug efficacy in cardiovascular disease |
| 10/28/2004 | WO2004018660A3 Novel lipases and uses thereof |
| 10/28/2004 | WO2004015084A3 Mutant e. coli appa phytase enzymes |
| 10/28/2004 | WO2004013313A3 Antisense nucleic acids |
| 10/28/2004 | WO2004003176A3 Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs |
| 10/28/2004 | WO2004003157A3 Gene regulation in transgenic animals using a transposon-based vector |
| 10/28/2004 | WO2004001009A3 Apo-2 ligand/trail variants and uses thereof |
| 10/28/2004 | WO2003105782A3 Specificity grafting of a murine antibody onto a human framework |
| 10/28/2004 | WO2003104415A3 Method to screen ligands using eukaryotic cell display |
| 10/28/2004 | WO2003100020A3 Methods and constructs for high yield expression of clostripain |
| 10/28/2004 | WO2003095613A3 Nucleic acids, polypeptides, and methods for modulating apoptosis |
| 10/28/2004 | WO2003093417A3 Lentiviral vector particles resistant to complement inactivation |
| 10/28/2004 | WO2003089573A3 Methods of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof |
| 10/28/2004 | WO2003087771A3 Method for making a molecularly smooth surface |
| 10/28/2004 | WO2003087329A3 Targeted cytocidal virionoids for antiangiogenesis |
| 10/28/2004 | WO2003087126A3 Heteroclitic analogs and related methods |
| 10/28/2004 | WO2003072600A8 Methods of screening molecular libraries for active molecules that restore the function of target proteins and peptides that restore the function of mutant p53 |
| 10/28/2004 | WO2003070908A3 Novel spinosyn-producing polyketide synthases |
| 10/28/2004 | WO2003052064A3 Clonal myeloma cell lines useful for manufacturing proteins in chemically defined media |
| 10/28/2004 | WO2003042657A3 Detection of nucleic acid sequences by cleavage and separation of tag-containing structures |
| 10/28/2004 | WO2003030833A3 Angiopoietin-2 specific binding agents |
| 10/28/2004 | WO2003022991A3 Compositions and methods of use of targeting peptides against placenta and adipose tissues |
| 10/28/2004 | WO2003022882A3 Method of increasing the contractility of a heart, a heart muscle or cells of a heart muscle |